Experimental CAR-T therapy shows promise for tough leukemia
NCT ID NCT05350787
First seen Feb 19, 2026 · Last updated May 25, 2026 · Updated 11 times
Summary
This early-stage study tested a new cell therapy called ThisCART19A in 10 adults with relapsed or refractory B-cell leukemia (a type of blood cancer that returned or didn't respond to standard treatment). The main goals were to check safety and find the right dose. Researchers tracked side effects and how well the therapy shrank cancer cells in the first three months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-ALL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Hospital of Zhejiang Medical Colleage Zhejiang University
Hangzhou, Zhejiang, 310003, China
-
The first affiliated hospital of medical college of zhejiang university
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.